pain – Page 4

Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis

ABSTRACT Measurement of plasma CBD concentration provided by transdermal absorption revealed linearity with 0.6–6.2 mg/day doses. Transdermal CBD gel significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose‐dependent manner. PWL recovered to near baseline level. Immunohistochemical analysis of spinal …

Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis Read More »

Aug 26 2019

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

ABSTRACT The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund’s adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. …

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Read More »

Aug 26 2019

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

ABSTRACT Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is limited in efficacy and …

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? Read More »

Aug 26 2019

Cannabinoids and the skeleton: from marijuana to reversal of bone loss.

ABSTRACT The active component of marijuana, Delta(9)-tetrahydrocannabinol, activates the CB1 and CB2 cannabinoid receptors, thus mimicking the action of endogenous cannabinoids. CB1 is predominantly neuronal and mediates the cannabinoid psychotropic effects. CB2 is predominantly expressed in peripheral tissues, mainly in pathological conditions. So far the main endocannabinoids, anandamide and 2-arachidonoylglycerol, have been found in bone …

Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Read More »

Aug 26 2019

Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

Cannabinoids and the skeleton: from marijuana to reversal of bone loss.

JOIN OUR NEWSLETTER

CONNECT WITH US

About

LEARN

Shop

These statements have not been evaluated by the FDA. This product is not intended diagnose, treat, cure or prevent disease.